|
Mar 21
|
J&J is latest company trying to get on Trump's good side with big U.S. investment
|
|
Mar 21
|
Johnson & Johnson Boosts Planned US Investment to More Than $55 Billion
|
|
Mar 21
|
Johnson & Johnson to Invest Over $55 Billion in U.S. in Next Four Years
|
|
Mar 21
|
Investing in the U.S.: Tracking Corporate Spending Pledges Under Trump
|
|
Mar 21
|
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease
|
|
Mar 21
|
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
|
|
Mar 21
|
Johnson & Johnson plans $55 billion in US investments over the next four years
|
|
Mar 21
|
J&J boosts US manufacturing as big pharma reshores
|
|
Mar 21
|
J&J boosts US investments by 25% over 4 years amid looming tariff threats
|
|
Mar 21
|
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
|
|
Mar 21
|
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
|
|
Mar 20
|
U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease
|
|
Mar 20
|
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
|
|
Mar 19
|
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
|
|
Mar 19
|
The Zacks Analyst Blog Highlights Visa, Johnson & Johnson, Thermo Fisher and AMREP
|
|
Mar 18
|
Top Stock Reports for Visa, Johnson & Johnson & Thermo Fisher Scientific
|
|
Mar 18
|
Johnson & Johnson (NYSE:JNJ) Gains FDA Fast Track For Nipocalimab In Treating Sjogren's Disease
|
|
Mar 18
|
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation
|
|
Mar 18
|
Got $300? Buy These 3 Top Dividend Stocks and Never Look Back.
|
|
Mar 17
|
Jim Cramer Says Johnson & Johnson (JNJ) Stock Could Fall to $160 Level
|